J&J looks to expand Rybrevant lung cancer indication to larger EGFR-positive population
Just two drugs are approved for NSCLC with EGFR exon 20 mutations: Takeda’s Exkivity and Johnson & Johnson’s Rybrevant.
But J&J is upping the ante …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
